Market Cap 1.52B
Revenue (ttm) 199.61M
Net Income (ttm) -17.48M
EPS (ttm) N/A
PE Ratio 95.30
Forward PE 30.69
Profit Margin -8.76%
Debt to Equity Ratio 5.21
Volume 681,900
Avg Vol 561,874
Day's Range N/A - N/A
Shares Out 37.04M
Stochastic %K 92%
Beta 0.02
Analysts Strong Sell
Price Target $70.71

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 733 4730
Address:
1A Burton Hills Boulevard, Suite 200, Nashville, United States
flash9875
flash9875 Feb. 4 at 3:19 PM
$HROW Bought 6200 more shares on that dip thank you
1 · Reply
CrossVenueIQ
CrossVenueIQ Feb. 4 at 1:42 PM
$HROW is a pharmaceutical company with a portfolio of branded and generic legacy products; it relies on acquisitions for growth and faces pricing pressure in its generic segment.
1 · Reply
NasdaqKnight
NasdaqKnight Feb. 4 at 1:03 PM
$HROW | B. Riley Buy | PT $74 Key drivers: • VEVYE script volume trends in focus • Jan ’26 NRx/TRx up 23% / 6% MoM vs Dec • Early boost from CVS Caremark Tier 1 preferred formulary (effective 1/1/26)
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:48 PM
$HROW Buckle up!
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:43 PM
$HROW VEVYE already strong in January 💪🏼wait for Feb, then Mar, and then Q2. It's getting better and better. -> ATH in H1. I feel it.
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:41 PM
$HROW BRILEY BUY PT $74 VEVYE script volume trends remain a key focus area for investors, with January 2026 NRx/TRx registering 23%/6% sequential M/M growth vs. December, notably capturing the early benefits of CVS Caremark Tier 1 preferred formulary status effective 1/1/26
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:41 AM
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:14 AM
$HROW Okay, but where is $10M of cash? Still waiting. They got new funding so they can pay fines.
1 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:03 AM
$HROW But Harrow is still waiting $9M of green dollars from OSRX🤠
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:02 AM
$HROW OSRX has their facility in California. This was very doubtful when OSRX was found guilty and now California wanted to help own city boys? But yea, happy Harrow exited that state.
1 · Reply
Latest News on HROW
Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update

Jan 22, 2026, 6:06 PM EST - 12 days ago

Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update


Harrow: Flirting With Missing 2025 Revised Guidance

Jan 12, 2026, 12:49 PM EST - 22 days ago

Harrow: Flirting With Missing 2025 Revised Guidance


Harrow to Present at Two Investor Conferences in December

Nov 24, 2025, 7:00 AM EST - 2 months ago

Harrow to Present at Two Investor Conferences in December


Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Nov 18, 2025, 7:00 AM EST - 2 months ago

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals


Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript

Nov 11, 2025, 2:11 PM EST - 3 months ago

Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript


Harrow Announces Third Quarter 2025 Financial Results

Nov 10, 2025, 4:05 PM EST - 3 months ago

Harrow Announces Third Quarter 2025 Financial Results


ImprimisRx Announces Leadership Changes

Oct 6, 2025, 7:00 AM EDT - 4 months ago

ImprimisRx Announces Leadership Changes


Harrow, Inc. (HROW) Analyst/Investor Day Transcript

Sep 27, 2025, 12:27 AM EDT - 4 months ago

Harrow, Inc. (HROW) Analyst/Investor Day Transcript


Harrow to Acquire Melt Pharmaceuticals

Sep 26, 2025, 7:00 AM EDT - 4 months ago

Harrow to Acquire Melt Pharmaceuticals


Harrow Launches Harrow Access for All (HAFA)

Sep 25, 2025, 4:05 PM EDT - 4 months ago

Harrow Launches Harrow Access for All (HAFA)


Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 15, 2025, 7:00 AM EDT - 5 months ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day


Harrow: Buy A Blend Of Value And Growth

Sep 12, 2025, 10:57 AM EDT - 5 months ago

Harrow: Buy A Blend Of Value And Growth


Harrow: A Classical GARP Stock

Sep 9, 2025, 1:11 PM EDT - 5 months ago

Harrow: A Classical GARP Stock


Harrow's Ambitious Guidance Puts It In The Proving Ground

Aug 14, 2025, 11:09 PM EDT - 6 months ago

Harrow's Ambitious Guidance Puts It In The Proving Ground


Harrow: Exciting Times In Store

Aug 13, 2025, 5:39 PM EDT - 6 months ago

Harrow: Exciting Times In Store


Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 2:47 PM EDT - 6 months ago

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript


Harrow Announces Second-Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 6 months ago

Harrow Announces Second-Quarter 2025 Financial Results


Harrow: Immense Upside Potential

Jul 9, 2025, 2:52 PM EDT - 7 months ago

Harrow: Immense Upside Potential


I Am Swimming In Dividends With +7% Yields

Jun 13, 2025, 8:30 AM EDT - 8 months ago

I Am Swimming In Dividends With +7% Yields

UMH


Harrow: Epic Growth & Operating Leverage On Full Display

May 28, 2025, 3:20 PM EDT - 8 months ago

Harrow: Epic Growth & Operating Leverage On Full Display


Harrow to Present at Two Investor Conferences in May

May 14, 2025, 7:00 AM EDT - 9 months ago

Harrow to Present at Two Investor Conferences in May


Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 10, 2025, 6:17 PM EDT - 9 months ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript


Harrow Announces First-Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 9 months ago

Harrow Announces First-Quarter 2025 Financial Results


NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 24, 2025, 10:00 AM EDT - 10 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.


Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 29, 2025, 4:30 PM EDT - 11 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)


Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 2:00 PM EDT - 11 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call


flash9875
flash9875 Feb. 4 at 3:19 PM
$HROW Bought 6200 more shares on that dip thank you
1 · Reply
CrossVenueIQ
CrossVenueIQ Feb. 4 at 1:42 PM
$HROW is a pharmaceutical company with a portfolio of branded and generic legacy products; it relies on acquisitions for growth and faces pricing pressure in its generic segment.
1 · Reply
NasdaqKnight
NasdaqKnight Feb. 4 at 1:03 PM
$HROW | B. Riley Buy | PT $74 Key drivers: • VEVYE script volume trends in focus • Jan ’26 NRx/TRx up 23% / 6% MoM vs Dec • Early boost from CVS Caremark Tier 1 preferred formulary (effective 1/1/26)
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:48 PM
$HROW Buckle up!
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:43 PM
$HROW VEVYE already strong in January 💪🏼wait for Feb, then Mar, and then Q2. It's getting better and better. -> ATH in H1. I feel it.
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:41 PM
$HROW BRILEY BUY PT $74 VEVYE script volume trends remain a key focus area for investors, with January 2026 NRx/TRx registering 23%/6% sequential M/M growth vs. December, notably capturing the early benefits of CVS Caremark Tier 1 preferred formulary status effective 1/1/26
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:41 AM
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:14 AM
$HROW Okay, but where is $10M of cash? Still waiting. They got new funding so they can pay fines.
1 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:03 AM
$HROW But Harrow is still waiting $9M of green dollars from OSRX🤠
0 · Reply
Finnish_boy
Finnish_boy Feb. 4 at 12:02 AM
$HROW OSRX has their facility in California. This was very doubtful when OSRX was found guilty and now California wanted to help own city boys? But yea, happy Harrow exited that state.
1 · Reply
Finnish_boy
Finnish_boy Feb. 3 at 11:59 PM
$HROW This is marketing and they inform own customers that the news have no impact on them but i find this form of press release pathetic.
0 · Reply
Finnish_boy
Finnish_boy Feb. 3 at 11:56 PM
$HROW Why OSRX press released this? I know, it's marketing, they want Imprimisrx customers. I am so happy ImprimisRX exited that toxic environment. OSRX also violated ImprimisRX trademark. They are going to pay 9M to ImprimisRX. ImprimisRX can cover that california fine from 9M lol https://osrxpharmaceuticals.com/osrx-confirms-ongoing-licensing-in-california/
1 · Reply
flash9875
flash9875 Feb. 3 at 9:28 PM
$HROW contact your mom....tell her thankyou
0 · Reply
HROW200
HROW200 Feb. 3 at 9:09 PM
$HROW Let’s see🤣
0 · Reply
HROW200
HROW200 Feb. 3 at 9:02 PM
$HROW Great follow up to Monday!! Let’s what the rest of the week holds.
0 · Reply
Finnish_boy
Finnish_boy Feb. 3 at 8:58 PM
$HROW Yes sir
0 · Reply
flash9875
flash9875 Feb. 3 at 8:58 PM
$HROW power stroke...
0 · Reply
flash9875
flash9875 Feb. 3 at 8:09 PM
$HROW saw this today..this speaks for hrow " Anyone who analyzes only the overall market ignores the fact that, in the long run, capital flows to where productivity, pricing power, and management quality are superior. Opportunistic investing, therefore, means selectively identifying mispricings, cyclical excesses, and structural winners, rather than blindly following average performance. Paradoxically, in a time of high index concentration and automated capital flows, more opportunities arise for selective investors because capital is allocated mechanically rather than analytically."
0 · Reply
flash9875
flash9875 Feb. 3 at 7:28 PM
$HROW pretty nice naz down 2% and we are up 3%...not bad. Folks are rotating into less risk ....we will only shine more as folks find out about the thesis.....
0 · Reply
flash9875
flash9875 Feb. 3 at 6:37 PM
$HROW 4 new reiterate buys on 2/2/26 see Tipranks. https://www.tipranks.com/stocks/hrow/forecast
0 · Reply
flash9875
flash9875 Feb. 3 at 6:35 PM
$HROW xp580/7.88= $63 per share
1 · Reply
Finnish_boy
Finnish_boy Feb. 3 at 3:11 PM
$HROW We're goin' up, up, up, it's our moment !!
0 · Reply